Published in Curr Pharm Des on January 01, 2012
Molecular imaging in pancreatic cancer--a roadmap for therapeutic decisions. Cancer Lett (2013) 0.83
In vivo fluorescence lifetime imaging for monitoring the efficacy of the cancer treatment. Clin Cancer Res (2014) 0.81
In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe. Technol Cancer Res Treat (2013) 0.78
Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res (2008) 1.96
Fluorescence lifetime imaging system for in vivo studies. Mol Imaging (2007) 1.83
Boron neutron capture therapy (BNCT) for glioblastoma multiforme: a phase II study evaluating a prolonged high-dose of boronophenylalanine (BPA). Radiother Oncol (2008) 1.62
Potential of PET to predict the response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J Nucl Med (2012) 1.52
[18F]FBEM-Z(HER2:342)-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging (2007) 1.50
Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and (18)F-labeled affibody molecules. J Nucl Med (2009) 1.33
The crosstalk between EGF, IGF, and Insulin cell signaling pathways--computational and experimental analysis. BMC Syst Biol (2009) 1.24
HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair. Mol Cancer Ther (2008) 1.13
Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11
HER2- and EGFR-specific affiprobes: novel recombinant optical probes for cell imaging. Chembiochem (2010) 1.10
Quantitative analysis of Her2 receptor expression in vivo by near-infrared optical imaging. Mol Imaging (2010) 1.07
HER2-specific affibody-conjugated thermosensitive liposomes (Affisomes) for improved delivery of anticancer agents. J Liposome Res (2008) 1.05
DESIGN OF LIPOSOMES CONTAINING PHOTOPOLYMERIZABLE PHOSPHOLIPIDS FOR TRIGGERED RELEASE OF CONTENTS. J Therm Anal Calorim (2009) 1.04
Normal tissue protection for improving radiotherapy: Where are the Gaps? Transl Cancer Res (2012) 1.03
'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol (2010) 1.03
Radiolabeling of HER2 specific Affibody(R) molecule with F-18. J Fluor Chem (2008) 0.99
Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer. Curr Opin Oncol (2009) 0.98
Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors. J Immunother (2009) 0.98
Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med (2010) 0.97
68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging (2011) 0.97
Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). J Control Release (2011) 0.96
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med (2011) 0.95
SimBoolNet--a Cytoscape plugin for dynamic simulation of signaling networks. Bioinformatics (2009) 0.95
In vivo fluorescence lifetime imaging monitors binding of specific probes to cancer biomarkers. PLoS One (2012) 0.94
Active targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors. Small (2013) 0.93
Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. J Neurooncol (2005) 0.89
Inverse treatment planning based on MRI for HDR prostate brachytherapy. Int J Radiat Oncol Biol Phys (2005) 0.89
HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res (2011) 0.88
Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. Mol Biol Rep (2011) 0.88
A novel 3D volumetric voxel registration technique for volume-view-guided image registration of multiple imaging modalities. Int J Radiat Oncol Biol Phys (2005) 0.87
In vivo method to monitor changes in HER2 expression using near-infrared fluorescence imaging. Mol Imaging (2012) 0.87
Polylactide-based paclitaxel-loaded nanoparticles fabricated by dispersion polymerization: characterization, evaluation in cancer cell lines, and preliminary biodistribution studies. J Pharm Sci (2014) 0.85
Accuracy of 3D volumetric image registration based on CT, MR and PET/CT phantom experiments. J Appl Clin Med Phys (2008) 0.84
Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PLoS One (2012) 0.84
Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. J Nucl Med (2014) 0.82
Determination of boron-containing compounds in urine and blood plasma from boron neutron capture therapy patients. The importance of using coupled techniques. Anal Chem (2002) 0.81
Nanoscintillator conjugates as photodynamic therapy-based radiosensitizers: calculation of required physical parameters. Radiat Res (2009) 0.80
The role of nuclear medicine in modern therapy of cancer. Tumour Biol (2012) 0.79
Ligand liposomes and boron neutron capture therapy. J Neurooncol (2003) 0.79
Proceedings of the Second NCI-SNMMI Workshop on Targeted Radionuclide Therapy. J Nucl Med (2015) 0.79
PET of HER2-positive pulmonary metastases with 18F-ZHER2:342 affibody in a murine model of breast cancer: comparison with 18F-FDG. J Nucl Med (2012) 0.79
In vivo assessment of HER2 receptor density in HER2-positive tumors by near-infrared imaging, using repeated injections of the fluorescent probe. Technol Cancer Res Treat (2013) 0.78
Accumulation of boron in human malignant glioma cells in vitro is cell type dependent. J Neurooncol (2004) 0.77
EGF-receptor targeted liposomes with boronated acridine: growth inhibition of cultured glioma cells after neutron irradiation. Int J Radiat Biol (2005) 0.77
Monte Carlo model of the Studsvik BNCT clinical beam: description and validation. Med Phys (2003) 0.75
Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget (2014) 0.75
Quality assurance of patient dosimetry in boron neutron capture therapy. Acta Oncol (2004) 0.75
Introductory experiments on ligand liposomes as delivery agents for boron neutron capture therapy. Int J Oncol (2003) 0.75